PERSANTINE
LOE ApproachingNDAORALTABLET
Approved
Dec 1961
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
2
Data completeness
2/8 — Basic
Drug data last refreshed Yesterday · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PERSANTINE (generic: dipyridamole) is an oral small-molecule platelet inhibitor approved in 1961 for cardiovascular indications. The drug works by inhibiting phosphodiesterase and adenosine deaminase, increasing adenosine levels to reduce platelet aggregation. It is primarily used as an adjunctive antiplatelet agent in patients with thromboembolic conditions.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30), signaling potential team downsizing or reallocation to newer assets.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Circulating Adenosine Levels Before and After Intravenous (IV) Persantine
Started Sep 2005
221 enrolled
IschemiaCoronary Disease
Persantine: Variation in Response Trial
Started Sep 2002
8 enrolled
Coronary Artery Disease
Career Relevance
Working on PERSANTINE offers stability in a legacy franchise but limited growth trajectory given LOE approach and zero linked job openings. Career advancement typically involves rotation to higher-growth portfolios rather than vertical expansion within this brand team.
Brand Manager
Worked on PERSANTINE at Boehringer Ingelheim? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.